



Alkermes to Host Conference Call to Discuss Results for Third Fiscal Quarter of 2004

February 5, 2004

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 5, 2004--Alkermes, Inc., (Nasdaq: ALKS) will host a conference call at 4:30pm EST on Wednesday, February 11, 2004 to discuss the company's financial results for the third fiscal quarter of 2004. Management will review the quarter and provide an update on the company.

The conference call may be accessed by dialing 1-888-243-0812 for domestic callers and 1-703-736-7293 for international callers. The conference call ID number is 385920. Additionally, the call will be webcast on the investor relations section of Alkermes' website at www.alkermes.com and archived on the site until Friday, February 13, 2004 at 5:00pm.

A replay of the conference call will be available from 7:30pm EST on February 11, 2004 through 5:00pm EST on February 13, 2004, and may be accessed by visiting Alkermes' website or by dialing 1-888-266-2081 for domestic callers and 1-703-925-2533 for international callers. The replay access code is 385920.

Alkermes, Inc. is an emerging pharmaceutical company developing products based on its sophisticated drug delivery technologies to enhance therapeutic outcomes. Our areas of focus include: controlled, extended-release of injectable drugs utilizing our ProLease(R) and Medisorb(R) delivery systems and the development of inhaled pharmaceutical products based on our proprietary Advanced Inhalation Research, Inc., ("AIR(R)") pulmonary delivery system. Our business strategy is twofold. We partner our proprietary technology systems and drug delivery expertise with many of the world's finest pharmaceutical companies and also develop novel, proprietary drug candidates for our own account. In addition to our Cambridge, Massachusetts headquarters, research and manufacturing facilities, we operate research and manufacturing facilities in Ohio.

CONTACT: Alkermes, Inc.
Rebecca Peterson, 617-583-6378
Director, Corporate Communications

SOURCE: Alkermes, Inc.